Abstract: The invention relates to using 2-methylene-19-nor-(20S)-1?,25-(OH)2D3 (2MD) or 2?-methyl-19-nor-(20S)-1?,25-(OH)2D3 (2MD) to prevent nephrotoxicity and/or fibrosis in a patient, preferably without causing hypercalcemia in the patient.

Abstract: The invention relates to using 2-methylene-19-nor-(20S)-1?,25-(OH)2D3 (2MD) or 2?-methyl-19-nor-(20S)-1?,25-(OH)2D3 (2AMD) to prevent nephrotoxicity and/or fibrosis in a patient, preferably without causing hypercalcemia in the patient.

Abstract: The invention relates to methods, compositions, and kits for detection of biomarkers. In one embodiment, the invention relates to a method for detecting AMR biomarkers in a biological sample. In another embodiment, the invention relates to a method for detecting, monitoring, diagnosing and predicting antibody mediated rejection. In yet another embodiment, the invention relates to a method for monitoring a subject for antibody mediated rejection comprising detecting BAFF or a BAFF variant in a biological sample. In still another embodiment, the invention relates to a kit for detecting BAFF in a urine sample.

Abstract: The invention relate to methods, compositions, and kits for detection of biomarkers. hi one embodiment, the invention relates to a method for detecting AMR biomarkers in a biological sample. In another embodiment, the invention relates to a method for detecting, monitoring, diagnosing and predicting antibody mediated rejection. In yet another embodiment, the invention relates to a method for monitoring a subject for antibody mediated rejection comprising detecting BAFF or a BAFF variant in a biological sample. In still another embodiment, the invention relates to a kit for detecting BAFF in a urine sample.

Abstract: Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Abstract: Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Abstract: A method of stabilizing kidney function in transplant patients is disclosed. In one embodiment, the method comprises the steps of kidney transplant patient, wherein the transplant patient is undergoing immunosuppressive therapy, with a sufficient amount of vitamin D compound whereby the kidney function stabilizes.

Abstract: Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Abstract: Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Abstract: A method of moderating transplant rejection in a transplant recipient comprising administering a dose of vitamin D compound effective to prevent transplant rejection is disclosed. Preferably, the recipient's susceptibility to opportunistic infections has not been compromised. Also preferably, the recipient has not suffered bone demineralization.